(0.40%) 5 112.00 points
(0.79%) 38 684 points
(0.67%) 17 768 points
(0.48%) $79.33
(0.44%) $2.04
(-0.15%) $2 306.20
(-0.67%) $26.65
(0.83%) $970.60
(-0.67%) $0.926
(-1.59%) $10.82
(-0.69%) $0.792
(0.51%) $91.59
Quarter results today
(bmo 2024-05-03)
Expected move: +/- 13.17%
Live Chart Being Loaded With Signals
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas...
Stats | |
---|---|
本日の出来高 | 2.13M |
平均出来高 | 1.58M |
時価総額 | 1.92B |
EPS | $0 ( 2024-03-01 ) |
次の収益日 | ( $0 ) 2024-08-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -12.94 |
ATR14 | $0.0100 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Konidaris Tasos | Buy | 87 720 | Class A Common Stock |
2024-03-12 | Konidaris Tasos | Sell | 30 790 | Class A Common Stock |
2024-03-12 | Konidaris Tasos | Sell | 87 720 | Restricted Stock Units |
2024-03-04 | Patel Chintu | Buy | 1 333 334 | Performance-Based Restricted Stock Units |
2024-03-04 | Patel Chintu | Buy | 370 370 | Restricted Stock Units |
INSIDER POWER |
---|
-8.46 |
Last 100 transactions |
Buy: 156 072 909 | Sell: 179 177 567 |
ボリューム 相関
Amneal Pharmaceuticals 相関
10 最も正の相関 | |
---|---|
ANAC | 0.962 |
AAC | 0.961 |
ESM-UN | 0.959 |
FTEV | 0.957 |
ACDI | 0.956 |
CPUH | 0.952 |
LII | 0.952 |
DMYS | 0.951 |
RCFA | 0.951 |
BCSF | 0.947 |
10 最も負の相関 | |
---|---|
TU | -0.951 |
WEI | -0.95 |
NJR | -0.947 |
BCE | -0.945 |
WDH | -0.944 |
TLK | -0.944 |
NUS | -0.941 |
AHT-PD | -0.94 |
TIXT | -0.938 |
DTLA-P | -0.935 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Amneal Pharmaceuticals 相関 - 通貨/商品
Amneal Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $2.39B |
総利益: | $820.57M (34.28 %) |
EPS: | $-0.480 |
FY | 2023 |
収益: | $2.39B |
総利益: | $820.57M (34.28 %) |
EPS: | $-0.480 |
FY | 2022 |
収益: | $2.21B |
総利益: | $784.71M (35.47 %) |
EPS: | $-1.690 |
FY | 2021 |
収益: | $2.09B |
総利益: | $768.97M (36.73 %) |
EPS: | $0.0700 |
Financial Reports:
No articles found.
Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。